Investing in NeoClone presents a unique opportunity to get involved with a privately-owned, maturing company that is poised for rapid growth. Our team of experienced scientists and business professionals have successfully developed and marketed excellent monoclonal antibodies developed with our proprietary NeoAb® process. We are continually adding antibody development services, such as Phage Display and Camelid antibodies for human therapeutics, to our portfolio as well as actively serving and collaborating in the diagnostics market.
As we advance our abilities to make therapeutic antibodies, NeoClone will be one of only a few companies that can help others bring these therapeutic products to market -- a market which is projected to reach $60 billion by 2016.
To learn more about investment opportunities, contact
our Chief Executive Officer.